Insulin secretion and immuno-genetic markers in diabetics with 'secondary failure' of oral hypoglycemic agents

Aust N Z J Med. 1985 Apr;15(2):209-12. doi: 10.1111/j.1445-5994.1985.tb04008.x.

Abstract

'Secondary failure' of oral hypoglycemics, in non-insulin dependent diabetics, has been attributed to dietary non-compliance, inadequate drug dosage, metabolic stress, or true drug failure. Progressive loss of beta cell function is a suggested mechanism for true drug failure but on the basis of little documented evidence. In view of this, we have measured basal and glucagon-stimulated C-peptide levels, human leukocyte antigen (HLA) types, and islet cell antibodies in 20 non-insulin dependent diabetics with 'secondary failure' of oral agents. There were 16 females and four males with a mean ideal body weight of 1.30 units and mean duration of diabetes of 9.5 years. Fasting insulin (mean +/- SD: 15.1 +/- 10.6 mU/l) and fasting C-peptide (2.3 +/- 1.2 micrograms/l) were normal or slightly elevated in all but one patient. Mean C-peptide increased from 2.3 +/- 1.2 micrograms/l to 3.5 +/- 2.2 micrograms/l (152% over basal) 6 minutes after 1 mg i.v. glucagon. In 15 patients the C-peptide response was greater than 130% of basal. Islet cell cytoplasmic antibodies were detected in only two patients. The distribution of HLA types was not significantly different from a control population, with no increase in DR3 or DR4. Thus, absolute insulin deficiency is uncommon in non-insulin dependent diabetics with 'secondary failure' of oral hypoglycemic agents and such patients do not exhibit the immuno-genetic markers of insulin-dependent diabetes.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Oral
  • Adult
  • Aged
  • Autoantibodies / analysis
  • Blood Glucose / analysis
  • C-Peptide / blood
  • Diabetes Mellitus, Type 2 / blood
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Diabetes Mellitus, Type 2 / genetics
  • Diabetes Mellitus, Type 2 / immunology
  • Female
  • Glucagon / pharmacology
  • HLA-DR Antigens
  • Histocompatibility Antigens Class II / analysis*
  • Humans
  • Hypoglycemic Agents / administration & dosage*
  • Insulin / metabolism*
  • Insulin Secretion
  • Islets of Langerhans / immunology
  • Male
  • Middle Aged

Substances

  • Autoantibodies
  • Blood Glucose
  • C-Peptide
  • HLA-DR Antigens
  • Histocompatibility Antigens Class II
  • Hypoglycemic Agents
  • Insulin
  • Glucagon